Nobivac Forcat

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Chlamydophila felis, Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus

Available from:

Intervet International BV

ATC code:

QI06AF01

INN (International Name):

Chlamydophila felis, Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus

Authorization status:

Expired

Summary of Product characteristics

Revised: June 2011
AN: 00364/2010
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac Forcat
(AT/DE: Nobivac RCP-Chlam)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Per dose of 1 ml:
Lyophilisate:
ACTIVE SUBSTANCES:

live attenuated feline calicivirus, strain F9:

4.6 log
10
PFU
1
;

live attenuated feline herpes virus type 1, strain G2620A:

5.2 log
10
PFU
1
;

live attenuated feline panleucopenia virus, strain MW-1:

4.3 log
10
CCID
50
2
;

live attenuated _Chlamydophila felis_, strain Baker:

2.3 log
10
CCID
50
2
.
1
PFU: Plaque-Forming Units
2
CCID
50
: Cell Culture Infective Dosis 50%
EXCIPIENTS:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate and solvent for suspension for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of cats:

to reduce the clinical signs caused by infection with feline
calicivirus and feline herpes
virus type 1,

to reduce the severity of the clinical signs caused by infection with
_Chlamydophila felis_,

to prevent the clinical signs, leucopenia and virus excretion caused
by infection with
feline panleucopenia virus.
Onset of immunity: for FCV and FHV: 4 weeks; for FPLV and _C. felis_:
3 weeks.
Duration of immunity for FCV, FHV, _C. felis_: 1 year, for FPLV: 3
years.
4.3
CONTRAINDICATIONS
See section 4.7
Page 1 of 5
Revised: June 2011
AN: 00364/2010
4.4
SPECIAL WARNINGS
Because antimicrobials may inactivate the live _C. felis_
vaccine strain, systemic
antimicrobial therapy should be avoided during vaccination and for a
two week period
afterwards.
Maternal antibodies, which may persist up to the age of 9-12 weeks,
can have a negative
influence on the efficacy of vaccination. In the presence of maternal
antibodies,
vaccination may not completely prevent the clinical signs, leucopenia
and virus excretion
following an FPLV infection, and may reduce the protection against a
_C. felis_ infection. In
such c